Neuronal and astroglial monoamine oxidase: pharmacological implications of specific MAO-B inhibitors.
Yu
P H
PH
Neuropsychiatric Research Unit, University of Saskatchewan, Saskatoon, Canada.
Davis
B A
BA
Boulton
A A
AA
D000818:Animals; D001253:Astrocytes / Q000187:drug effects* / Q000201:enzymology; D004298:Dopamine / Q000378:metabolism*; D008959:Models, Neurological; D008995:Monoamine Oxidase / Q000502:physiology*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009410:Nerve Degeneration; D009419:Nerve Tissue Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D009474:Neurons / Q000187:drug effects* / Q000201:enzymology; D010084:Oxidation-Reduction; D010627:Phenethylamines / Q000494:pharmacology; D051381:Rats; D012642:Selegiline / Q000494:pharmacology; D013329:Structure-Activity Relationship
D008996:Monoamine Oxidase Inhibitors; D009419:Nerve Tissue Proteins; D010627:Phenethylamines; D012642:Selegiline; C029261:phenethylamine; D008995:Monoamine Oxidase; D004298:Dopamine